NASDAQ:OBSV ObsEva (OBSV) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free OBSV Stock Alerts $0.0050 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.0050▼$0.005050-Day Range$0.00▼$0.0852-Week Range$0.08▼$2.14Volume100,000 shsAverage Volume8.94 million shsMarket Capitalization$389,855.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsSEC FilingsSocial Media Get ObsEva alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About ObsEva Stock (NASDAQ:OBSV)ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Read More OBSV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OBSV Stock News HeadlinesApril 20, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV)April 3, 2024 | globenewswire.comObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 19, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsFebruary 28, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 26, 2024 | benzinga.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesNovember 11, 2023 | morningstar.comObsEva SA OBSNNovember 11, 2023 | morningstar.comObsEva SA OBSEFApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 18, 2023 | fool.comObsEva (NASDAQ: OBSV)March 31, 2023 | finance.yahoo.comObsEva Files Year End 2022 Financial StatementsMarch 15, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 13, 2023 | markets.businessinsider.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | finance.yahoo.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 3, 2023 | benzinga.comWhy Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day SessionMarch 3, 2023 | investorplace.comWhy Is ObsEva (OBSV) Stock Up 93% Today?February 24, 2023 | investorplace.comWhy ObsEva (OBSV) Stock Is Down 36% TodayFebruary 24, 2023 | finance.yahoo.comObsEva Announces Strategic Reorganization to Consolidate Operations in SwitzerlandJanuary 12, 2023 | uk.finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 19, 2022 | finance.yahoo.comObsEva Announces Dismissal of Moratorium ProceedingsDecember 14, 2022 | finance.yahoo.comObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request FilingDecember 1, 2022 | finance.yahoo.comObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue EstimatesDecember 1, 2022 | finance.yahoo.comObsEva Announces Third Quarter 2022 Financial Results and Provides a Business UpdateOctober 27, 2022 | finance.yahoo.comObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium ProceedingsOctober 16, 2022 | finance.yahoo.comObsEva SA (OBSV)October 14, 2022 | markets.businessinsider.comObsEva : China Approves Yuyuan Bioscience's IND Application For Phase 1 Trial Of NolasibanOctober 13, 2022 | finance.yahoo.comObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China - Yahoo FinanceSee More Headlines Receive OBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OBSV CUSIPN/A CIK1685316 Webwww.obseva.com Phone(122) 552-3840FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-416.36% Return on Assets-92.01% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual Sales$20.11 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book0.01Miscellaneous Outstanding Shares77,971,000Free Float66,743,000Market Cap$389,855.00 OptionableNot Optionable Beta0.68 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesWilliam M. BrownChief Executive & Financial OfficerElke BestelVP, Head-Drug Safety & PharmacovigilanceKatja BuhrerChief Strategy OfficerKey CompetitorsAmpio PharmaceuticalsNYSE:AMPEAllarity TherapeuticsNASDAQ:ALLRAptevo TherapeuticsNASDAQ:APVOAthersysNASDAQ:ATHXChina SXT PharmaceuticalsNASDAQ:SXTCView All Competitors OBSV Stock Analysis - Frequently Asked Questions How have OBSV shares performed in 2024? ObsEva's stock was trading at $0.0350 on January 1st, 2024. Since then, OBSV stock has decreased by 85.7% and is now trading at $0.0050. View the best growth stocks for 2024 here. How were ObsEva's earnings last quarter? ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.23. What other stocks do shareholders of ObsEva own? Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA). When did ObsEva IPO? ObsEva (OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. How do I buy shares of ObsEva? Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OBSV) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
